A feasibility study of Pemetrexed/Bevacizumab in elderly patients with advanced non-small cell lung cancer (TORG1015)

Not Applicable

• Conditions: on-small cell lung cancer

• Registration Number: JPRN-UMIN000004263
• Lead Sponsor: Thoracic Oncology Research Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with brain metastasis. 2. Patients with current or previous hemoptysis. 3. Patients treated with radiation therapy for thoracic region. 4. Patients with active severe infections. 5. Patients who have fever of over 38 degrees. 6. Patients with serious complication (cardiac affection, interstitial pneumonia, uncontrollable hypertension, or uncontrollable diabetes mellitus, etc.) 7. Patients with massive ascites, pleural or pericardial effusion. 8. Patients with concomitant malignancy. 9. Patients with history of drug allergies. 10. Patients with uncontrollable gastrointestinal ulceration. 11. Patients with current or previous (within one year) history of gastrointestinal perforation. 12. Patients treated with anticoagulation therapy. 13. Inappropriate patients for this study judged by the physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Toxicity

Secondary Outcome Measures

Name	Time	Method
Response rate, Progression-free survival, Overall survival, Completion proportion of 3 cycles